This is a working overview of Working solution, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2026-02-23 and is reviewed periodically as new material appears.
Both receptors are class B G protein-coupled receptors that signal largely through Gs-mediated cyclic AMP production. Activation within pancreatic islets increases glucose-dependent insulin secretion and suppresses glucagon release when glucose is elevated. Outside the pancreas, signaling in the central nervous system and gut appears to influence appetite and gastric emptying. The relative contribution of each receptor to observed clinical effects remains under investigation, and the two pathways are not simply additive in practice.
Reported outcomes in large trials include dose-dependent weight reduction and improvements in glycemic markers over periods ranging from several months to more than a year. Whether the compound alters long-term cardiovascular or renal outcomes is being examined in dedicated outcome studies, so those questions remain open. Labeling describes gastrointestinal effects such as nausea and diarrhea, which tend to appear during dose escalation. Discontinuation rates and the durability of effects after treatment stops vary across study populations and are still debated.
Tirzepatide is a synthetic peptide developed as a dual agonist at the glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 receptors. Its structure is built on a GIP-derived backbone with non-natural amino acid substitutions and a fatty diacid side chain that promotes albumin binding and slows clearance. That modification supports once-weekly subcutaneous dosing. Registrational trial programs reported reductions in body weight and glycated hemoglobin alongside the drug's glycemic effects.
Bulk peptide material is normally characterised by reversed-phase high-performance liquid chromatography, which separates the target sequence from truncation products and other closely related impurities. Ultraviolet detection near 214 nanometres is common because the peptide backbone absorbs in that region. Mass spectrometry, usually electrospray ionisation coupled to a mass analyser, is used to confirm the molecular mass. Because the molecule carries a lipophilic side chain, gradient methods often need a relatively high organic modifier fraction to elute it within a practical retention window.
Like most synthetic peptides of this size, the material is commonly supplied as a lyophilised powder that appears white to off-white. It dissolves in aqueous buffers and in mixtures of water with a small proportion of organic solvent, though the fatty acid portion reduces solubility in pure water relative to short peptides. Hygroscopic behaviour is reported for many peptide powders, so weighing is usually performed quickly and under controlled humidity. Working solutions are typically prepared fresh and kept cold.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic 39-residue peptide | GIP-derived backbone with non-natural residues |
| Molar mass | Approximately 4.8 kDa | Peptide chain plus linker and lipid modifications |
| Appearance | White to off-white powder | Typical of lyophilized research material |
| Solubility | Soluble in water and aqueous buffer | Practically insoluble in nonpolar solvents |
| Storage temperature | Typically −20 °C for dry powder | Solutions usually held at 2–8 °C short term |
Tirzepatide is a synthetic peptide composed of 39 amino acids. It acts as a dual agonist at two incretin receptors, the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor. The molecule was designed by modifying the native sequence of glucose-dependent insulinotropic polypeptide to improve metabolic stability and extend its circulation time. Its structure includes several non-natural amino acid residues and a fatty acid side chain. These features distinguish it from earlier single-receptor incretin analogs studied in the same period.
The compound first appeared in the scientific literature as an investigational agent for type 2 diabetes. Clinical development proceeded through phase 1, phase 2, and phase 3 programs that measured glycemic control as a primary endpoint while recording body weight as a secondary outcome. Regulatory approval in the United States followed in 2022 for glycemic control, and a separate indication for chronic weight management was added later. Subsequent trials have examined cardiovascular outcomes in adults with elevated cardiovascular risk. Debates continue over how much of the observed effect derives from each receptor arm.
Structural work on the molecule centers on a C20 fatty diacid moiety attached through a linker to the peptide backbone. This side chain promotes reversible binding to serum albumin, which slows renal clearance and supports a prolonged action profile. The peptide backbone incorporates aminoisobutyric acid substitutions that limit recognition by digestive enzymes. Together these modifications produce a molecule that is stable enough for subcutaneous delivery but still dependent on careful manufacturing control. Analytical characterization of the active pharmaceutical ingredient typically follows the conventions used for other synthetic peptides.
Routine characterization relies on reversed-phase high-performance liquid chromatography, often coupled to mass spectrometry, to confirm identity and estimate purity. Peptide mapping after enzymatic digestion verifies the amino acid sequence and locates appended groups such as the fatty acid chain. Size-exclusion chromatography detects aggregates and fragments, while ion-exchange chromatography resolves charge variants. Circular dichroism and nuclear magnetic resonance supply secondary and higher-order structural information in research settings. No single technique covers every attribute, so laboratories combine orthogonal methods and compare outcomes against a reference standard where one exists.
Purified material is typically handled as a lyophilized powder kept at or below minus twenty degrees Celsius, shielded from light and moisture. In that state the solid remains stable for extended periods, although repeated freeze-thaw cycling can encourage aggregation. Once dissolved, aqueous solutions are less durable and are generally held cold and used within a brief window. Buffer composition, pH and ionic strength all influence degradation rates, and mildly acidic to neutral conditions are commonly examined. Actual shelf life depends on formulation, concentration and container, so stability limits are established experimentally rather than assumed.
The peptide activates two G protein-coupled receptors, GIPR and GLP-1R. Binding triggers adenylyl cyclase activity and raises intracellular cyclic AMP in pancreatic beta cells, which potentiates insulin release when glucose is elevated. Signaling in the central nervous system is associated with reduced appetite and lower energy intake, while effects on gastric emptying and glucagon secretion are also reported. Because activity at both receptors is retained, the pharmacological profile is often described as incretin-based rather than selective for a single receptor.
After subcutaneous injection, absorption is gradual, and peak plasma levels are generally reached within one to three days. Albumin binding extends the apparent half-life to roughly five days, which supports a weekly administration schedule. Metabolism proceeds mainly through proteolytic cleavage of the peptide backbone and beta-oxidation of the fatty acid chain, rather than through cytochrome P450 pathways. Eliminated fragments are largely recycled through general protein turnover, and excretion of intact drug in urine is minimal. These properties distinguish the molecule from short-acting incretin mimetics.
Tirzepatide is a synthetic peptide of 39 amino acids that carries a C20 fatty diacid side chain attached through a linker. Its molecular formula is C225H348N48O68, and its molecular weight is about 4813 daltons. The compound belongs to the incretin mimetic class and is administered by subcutaneous injection. The fatty acid chain promotes binding to serum albumin, which slows renal clearance and extends the circulation time of the molecule. It was identified during screening of sequences derived from glucose-dependent insulinotropic polypeptide.
Tirzepatide activates both the glucose-dependent insulinotropic polypeptide receptor and the glucagon-like peptide-1 receptor, making it a dual agonist rather than a selective agent. Engagement of the GLP-1 receptor is linked to glucose-dependent insulin release, slower gastric emptying, and reduced appetite signalling. The relative contribution of the GIP arm remains an active research question; proposed roles include improved insulin sensitivity and altered adipose tissue handling. Receptor occupancy studies suggest the molecule interacts with both targets at circulating concentrations achieved during therapy.
Development began in the 2010s, when researchers modified a GIP-based scaffold to add GLP-1 activity and then attached the fatty diacid to lengthen its half-life. Clinical evaluation proceeded through large phase 3 programmes in type 2 diabetes and in obesity, and regulators in the United States cleared the compound for type 2 diabetes in 2022 and for chronic weight management in 2023. Several cardiovascular and metabolic outcome studies are still reporting, so the picture of long-term benefit and risk is incomplete. Approvals in other regions followed on different timelines.
Therapeutic touch (TT), or non-contact therapeutic touch (NCTT), also generically called healing touch, is a pseudoscientific energy therapy which practitioners claim promotes healing and reduces pain and anxiety. "Therapeutic Touch" is a registered trademark in Canada for the "[s]tructured and standardized healing practice performed by practitioners trained to be sensitive to the receiver's energy field that surrounds the body;...no touching is required." Practitioners of therapeutic touch state that by placing their hands on, or near, a patient, they are able to detect and manipulate what they say is the patient's energy field. One highly cited study, designed by the then-nine-year-old Emily Rosa and published in the Journal of the American Medical Association in 1998, found that practitioners of therapeutic touch could not detect the presence or absence of a hand placed a few inches above theirs when their vision was obstructed. Simon Singh and Edzard Ernst concluded in their 2008 book Trick or Treatment that "the energy field was probably nothing more than a figment in the imaginations of the healers". The American Cancer Society noted, "Available scientific evidence does not support any claims that TT can cure cancer or other diseases." A 2004 Cochrane review found no good evidence that it helped with wound healing, but the authors withdrew it in 2016 out of "serious concerns over the validity of included studies".
== Types == There are membrane-bound (type 1, guanylate cyclase-coupled receptor) and soluble (type 2, soluble guanylate cyclase) forms of guanylate cyclases. Membrane bound guanylate cyclases include an external ligand-binding domain (e.g., for peptide hormones such as BNP and ANP), a transmembrane domain, and an internal catalytic domain homologous to adenylyl cyclases. Recently, a directly light-gated guanylate cyclase has been discovered in an aquatic fungus. In the mammalian retina, two forms of guanylate cyclase have been identified, each encoded by separate genes; RETGC-1 and RETGC-2. RETGC-1 has been found to be expressed in higher levels in cones compared to rod cells. Studies have also shown that mutations in the RETGC-1 gene can lead to cone-rod dystrophy by disrupting the phototransduction processes.
Following trial and conviction at Wood Green Crown Court, Patrick Simms is sentenced to nine years in prison for the rape of a 15-year-old girl he committed after meeting the girl at a leisure centre in Hackney in 1987. 22 July – Seb Dance, the Deputy Mayor of London, confirms that day travelcards will be phased out for travel within London. 23 July – Newcastle's Northern Pride is forced to end early after heavy rain makes the festival site unsafe. 24 July – The Metropolitan Police announce that radical preacher Anjem Choudary has been charged with three terror offences. 25 July – Data published by the Department for Levelling Up, Housing and Communities indicates the number of homeless people to be at a 25-year high, with 105,000 households in England living in temporary accommodation, a figure that includes 131,000 children. Data released by the Metropolitan Police indicates that a 13-week campaign by Just Stop Oil has cost the force £7.7m to police. 26 July – The Court of Appeal overturns the 2004 conviction of Andrew Malkinson, convicted of a 2003 rape in Salford on unreliable evidence. 27 July – The UK government confirms that COVID-19-era licencing rules in England allowing pubs to sell takeaway drinks will end on 30 September. 28 July – The High Court rules that the planned extension of London's Ultra Low Emission Zone is lawful after rejecting a legal challenge from five Conservative-led local authorities.
Sources: en.wikipedia.org
Efgartigimod alfa, sold under the brand name Vyvgart, is a medication used to treat myasthenia gravis. Efgartigimod alfa is a neonatal Fc receptor blocker and is a new class of medication. It is an antibody fragment that binds to the neonatal Fc receptor (FcRn), preventing FcRn from recycling immunoglobulin G (IgG) back into the blood. The medication causes a reduction in overall levels of IgG, including the abnormal acetylcholine receptor (AChR) antibodies that are present in myasthenia gravis. It is also available coformulated with hyaluronidase. The most common side effects include respiratory tract infections, headache, urinary tract infections, and paresthesia (numbness, tingling). It was approved for medical use in the United States in December 2021, and in the European Union in August 2022. The US Food and Drug Administration (FDA) considers it to be a first-in-class medication.
Thermodynamic stability of proteins represents the free energy difference between the folded and unfolded protein states. This free energy difference is very sensitive to temperature, hence a change in temperature may result in unfolding or denaturation. Protein denaturation may result in loss of function, and loss of native state. The free energy of stabilization of soluble globular proteins typically does not exceed 50 kJ/mol. Taking into consideration the large number of hydrogen bonds that take place for the stabilization of secondary structures, and the stabilization of the inner core through hydrophobic interactions, the free energy of stabilization emerges as small difference between large numbers.
== Explanation of anomalous behaviour == Water is a polar molecule, where the centers of positive and negative charge are separated; so molecules will align with an electric field. The extensive hydrogen bonded network in water tends to oppose this alignment, and the degree of alignment is measured by the relative permittivity. Water has a high relative permittivity of about 80 at room temperature; because polarity shifts are rapidly transmitted through shifts in orientation of the linked hydrogen bonds. This allows water to dissolve salts, as the attractive electric field between ions is reduced by about 80–fold. Thermal motion of the molecules disrupts the hydrogen bonding network as temperature increases; so relative permittivity decreases with temperature to about 7 at the critical temperature. At 205 °C the relative permittivity falls to 33, the same as methanol at room temperature. Thus water behaves like a water–methanol mixture between 100 °C and 200 °C. Disruption of extended hydrogen bonding allows molecules to move more freely (viscosity, diffusion and surface tension effects), and extra energy must be supplied to break the bonds (increased heat capacity).
Sources: en.wikipedia.org
==== Antigonadotropic effects ==== CPA has potent antigonadotropic effects via its progestogenic activity. It blunts the gonadotropin releasing hormone (GnRH)-induced secretion of gonadotropins, and accordingly, markedly suppresses circulating levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) at sufficiently high doses. Consequently, levels of progesterone, androstenedione, testosterone, DHT, and estradiol are also markedly lowered at sufficiently high dosages, while an elevation in sex hormone-binding globulin (SHBG) and prolactin levels is observed. The effective dosage of CPA for inhibition of ovulation in women, this being an antigonadotropic effect, is 1 mg/day. CPA alone has been found to suppress ovulation in 3 of 5 women at a dose of 0.5 mg/day and in 5 of 5 women at a dose of 1 mg/day in studies. Ovulation inhibition with 1–2 mg/day CPA in combination with 1–2 mg/day estradiol valerate as a birth control pill (brand name Femilar) occurred in 94.4% of 108 women during the third treatment cycle in one study and in almost 100% of 26 women over 12 treatment cycles in another study (except for one woman who ovulated during her first treatment cycle). Oral CPA has been studied at low dosages of 5 to 20 mg/day as a potential male hormonal contraceptive. A dosage of as low as 5 to 10 mg/day oral CPA has been found to suppress circulating testosterone levels in men by 50 to 70%.
The drills continued the following day and were closely monitored by the militaries of both Australia and New Zealand. The New Zealand Government allocates NZ$200 million of funding for the City Rail Link to removing level crossings in order to ease traffic congestion in Auckland. Andrew Bayly resigns as Minister of Commerce and Consumer Affairs after he "placed a hand" on a staff member's upper arm on 18 February, in what Bayly acknowledges as "overbearing" behavior. 22 February: Police investigate five suspected overnight church arson attempts in Masterton. Chinese warships conduct a second live firing exercise in the Tasman Sea. Prime Minister Luxon confirms that Australian and New Zealand naval forces including HMNZS Te Kaha are monitoring the Chinese vessels. 23 February: LGBT supporters gather in Auckland's Albert Park to protest against Destiny Church's disruption of Pride events on 15 February. The New Zealand Police confirm they are investigating graffiti at the former location of Auckland's Kadimah School, which was discovered on 6 February. 24 February – The Police confirmed they have seized 76 gang patches and filed 337 charges for alleged insignia breaches under the Gangs Act 2024. 25 February: Immigration Minister Erica Stanford announces the Government will ease residency rules to recruit more primary school teachers from overseas. Executive director Helen Potiki and legal counsels Nick Whittington and Kristy McDonald KC resign from the second phase of the Royal Commission of Inquiry into COVID-19 Lessons Learned.
=== Flow cell === The eluant from the column passes through one or more flow cells to measure the concentration of protein in the eluant (by UV light absorption at 280 nm). The conductivity cell measures the buffer conductivity, usually in millisiemens/cm, which indicates the concentration of salt in the buffer. A flow cell which measures pH of the buffer is also commonly included. Usually each flow cell is connected to a separate electronics module which provides power and amplifies the signal.
Sources: en.wikipedia.org
It acts as an agonist at both the GIP and GLP-1 receptors, two related class B G protein-coupled receptors. This dual activity distinguishes it from single-receptor GLP-1 agonists. The clinical consequences of engaging both receptors are still being characterized.
It is given by subcutaneous injection, generally on a weekly schedule. Dosing usually begins low and increases in steps to limit gastrointestinal side effects. Formulated product is supplied as a ready-to-use pen or vial in most markets.
No. Receptor engagement is documented, but how central appetite circuits, gut signals, and insulinotropic effects combine is incompletely resolved. Investigators continue to separate GIP-driven from GLP-1-driven contributions in animal and human models.
It separates molecules by hydrophobicity, which is effective for distinguishing an intact peptide from truncated or chemically modified forms. A C18 column with an acidic water-organic mobile phase is a standard configuration.